Why Nuvalent (NUVL) Is Among the Best Mid Cap Biotech Stocks to Buy

Yahoo

29-03-2025

We recently published a list of the . In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against the other best mid cap biotech stocks to buy.
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector. He said that looking at the denominator of biotech stocks in the public market, we're standing at the 700-800 range, depending upon the day. Almost a quarter of these have enterprise values in negative territory. That basically means that investors and companies, in some respects, have exhausted options. For any value to be created, it is necessary to shift focus and devise another plan of attack through an asset they don't currently own, and resuscitate the company.
In some respects, investors and analysts are always looking for a clear pathway for biotech as a sector to perform better. However, Holz said we are in a tough place if a quarter of the index is filled with companies with more cash than the market cap. That is why he suggested, which some people consider somewhat hyperbolic, getting rid of the tail here, as there are too many assets out there.
Thousands of biotech companies are competing against each other for tiny market or revenue opportunities. Holz opined that venture funds should stop making so many companies that end up superseding each other in a few years. It would be helpful to dissolve all the biotech stocks with negative values and return the cash to shareholders.
READ ALSO: and .
Biotechs pose a tempting scenario, as a company's stock could be worth $5 with a potential blockbuster drug in the pipeline that could cure even cancer. The company's stock could surge to hundreds of dollars if the clinical trial succeeds. However, at the same time, it could plunge down to $0 if the trial doesn't. Holz thus says that the sector is incredibly tempting, and thousands of investors put their careers on the line daily to attempt to figure this out.
He characterized biotech as one of the only sectors in all of equities where single stock picking is the only way to make money. Building on his years-long experience covering the industry, he said that the index has barely been up since the past decade. It has been essentially flat. Meanwhile, every other index that one can find has doubled or more. Therefore, there is an obvious issue with the broader complex. But if you find the right asset, you can kill it in the sector.
We sifted through stock screeners, financial media reports, and ETFs to compile a list of 30 biotech stocks with a market cap between $2 billion and $10 billion. We then selected the top 10 with the highest number of hedge fund holders, as of Q4 2024, and ranked them in ascending order. We sourced the hedge fund sentiment data from Insider Monkey's database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points ().
A physician standing in a lab, with vials of biopharmaceuticals in hand.
Market Cap: $5.37 billion
Number of Hedge Fund Holders: 50
Nuvalent, Inc. (NASDAQ:NUVL) is a biopharmaceutical company developing precisely targeted therapies for cancer patients. It focuses on small molecules that can minimize adverse events, overcome resistance, and address metastases. The company has a robust pipeline, including ROS1 NSCLC, ALK NSCLC, and HER2 NSCLC.
H.C. Wainwright analyst Swayampakula Ramakanth maintained their bullish stance on Nuvalent, Inc. (NASDAQ:NUVL), giving a Buy rating on February 28. The analyst based their position on various factors, including the company's strategic implementation of Expanded Access Programs (EAPs) for their investigational drugs, zidesamtinib and neladalkib. The programs have high demand, reflecting the growing interest from patients and physicians for new treatment options in clinical development. They also present Nuvalent, Inc. (NASDAQ:NUVL) with a cost-effective platform for boosting patient exposure to their treatment and building a broader prescriber base. The analyst expects this to support rapid market adoption after regulatory approval.
In addition, the company's progress in clinical trials also supports the analyst's bullish sentiments. Nuvalent, Inc. (NASDAQ:NUVL) is on track to release pivotal data for zidesamtinib in H1 2025, and a potential FDA approval can be expected in 2026.
Overall, NUVL ranks 7th on our list of the best mid cap biotech stocks to buy. While we acknowledge the potential of NUVL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NUVL but that trades at less than 5 times its earnings, check out our report about the .
READ NEXT: and .
Disclosure: None. This article is originally published at .